期刊文献+

葡萄膜黑色素瘤基因突变、染色体变异与预后 被引量:1

Gene mutations,chromosome aberrations and prognosis of uveal melanoma
下载PDF
导出
摘要 葡萄膜黑色素瘤(UM)的发病率仅次于皮肤黑色素瘤,是成人常见的原发性眼内恶性肿瘤。近年来的研究认为,UM的发生与基因突变、染色体变异、分子通路的异常改变等有关,其中发生突变的基因包括GNAQ基因、GNAlJ基因、微小RNA(miRNA)(miR-34a、miR-182、miR-137)等。基因GNAQ、GNA11的突变,通过激活相关通路,如MEK/ATK途径,导致UM的转移,影响肿瘤的预后;不同的微小RNA(miRNA)靶定相应的基因,并通过相应的通路影响肿瘤的预后;还有端粒酶逆转录酶基因的突变都通过调节特定的分子通路影响肿瘤的发生、发展、转移及预后。分子遗传学研究证实,大多数UM患者存在1、3、6、8、9号染色体的改变,导致染色体发生缺失或增加使肿瘤更易发生侵袭和转移。本文总结UM预后的基因突变与染色体变异,为UM的治疗提供新的靶点。 Incidence of Uveal melanoma (UM) , is only secondary to cutaneous melanoma and is common primary intraocular malignant tumor of in adults. Recent studies suggest that its occurrence is related with gene mutation,chromosome aberrations and molecular pathway abnormalities. The mutations include GNAQ gene, GNAll gene,microRNA (miRNA) (miR-34a, miR-182, miR-137). Mutations of GNAQ gene and GNAll gene activate relevant pathways, such as MEK/ATK pathway,to promote UM metastasis, which makes the poor prognosis. Different miRNAs target the correspending genes and affect the prognosis. And the mutations of tclomerase reverse transcriptase,all of them adjust the specific molecular pathways to affect tumor occurrence, development, metastasis and prognosis. Molecular genetic studies confirm that most patients with UM have chromosome 1,3,6,8,9 alterations, making the chromosome gain or less,leading to more susceptible invasion and metastasis and influencing prognosis. This paper reviewed the gene mutation and chromosome aberrations in order to provide new targets for the treatment of UM.
作者 张明雪 张虹
出处 《中华实验眼科杂志》 CAS CSCD 北大核心 2015年第11期1052-1056,共5页 Chinese Journal Of Experimental Ophthalmology
关键词 葡萄膜黑色素瘤 基因突变 染色体变异 GNAQ基因 GNA11基因 Uveal melanoma Gene mutation Chromosome aberrations GNAQ gene GNAll gene
  • 相关文献

参考文献52

  • 1Bedikian AY. Metastatic uveal melanoma therapy : current options [ J ]. Int Ophthalmol Clin ,2006,46( 1 ) : 151-166.
  • 2McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the US [ J ]. Cancer, 2005,103 ( 5 ) : 1000-1007. doi : 10. 1002/cncr. 20866.
  • 3Ramaiya K J, Harbour JW. Current management of uveal melanoma[ J]. Expert Rev Ophthalmol,2007,2 ( 6 ) : 939-946.
  • 4Yirgili G, Gatta G, Ciccolallo L, et al. incidence of uveal melanoma in Europe [ J ]. Ophthalmology, 2007,114 ( 12 ) : 2309 -2315.
  • 5Singh AD, Topham A. Incidence of uveal melanoma in the United States : 1973--1997 [ J ]. Ophthalmology ,2003,110 ( 5 ) : 956 -961.
  • 6Damato BE, Dopierala J, Klaasen A, et al. Multiplex ligation-dependentprobe amplification of uveal melanoma:correlation with metastatic death [ J ]. Invest Ophthalmol Vis Sci, 2009,50 ( 7 ) : 3048 -3055. dot: 10. 1167/toys. 08-3165.
  • 7Tsianakas A, B8hm MR, Getova V, et al. Skin metastases in metastatic uveal melanoma:GNAQ/GNA11 mutational analysis as a valuable tool [J]. Br J Dermatol,2013,169(1) : 160-163. doi:lO, llll/bjd. 12291.
  • 8Sibbritt T, Patel HR, Preiss T. Mapping and significance of the mRNA methylome [ J ]. Wiley Interdiscip Rev RNA, 2013,4 ( 4 ) : 397 - 422. dot : 10. 1002/wrna. 1166.
  • 9Keek B ,Ellmann C ,Stoehr R,et al. Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma [J]. Urol Oncol,2014,32 (8) : 1234-1239. dot: 10. 1016/j. urolonc. 2014.06. 016.
  • 10Climent J, Garcia JL, Man ]H,et al. Characterization of breast cancer by array comparative genomic hybridization [ J ]. Biochem Cell Biol,2007, 85 (4) : 497-508.

二级参考文献10

  • 1Hurst EA, Harbour JW, Cornelius LA. Ocular melanoma:a review and therelationship to cutaneous melanoma [J]. Arch Dermatol, 2003, 139(8): 1067 - 1073.
  • 2He L,Hannon GJ. MicroRNAs :smatt RNAs with a big role in gene regulation [J]. Nat Rev Genet, 2004, 5 (7):522--531.
  • 3Kumar MS, Lu J, Mercer KL, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis [J]. Nat Genet, 2007,39 (5) : 673--677.
  • 4Redshaw N, Wheeler G, Hajihosseini MK, et al. MicroRNA-449 is a putative regulator of choroid plexus development and function[J]. Brain Res, 2009, 1250:20--26.
  • 5Jiang WG, Martin TA, Parr C, et al. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies [J]. Crit Rev Oncol Hematol, 2005,53 (1):35--69.
  • 6Yan DS, Zhou XT, Chen XY, et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met[J]. Invest Ophthalmol Vis Sci, 2009,50(4) : 1559-- 1565.
  • 7Corney DC, Flesken-Nikitin A, Godwin AK, et al. MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth[J]. Cancer Res, 2007, 67 (18) : 8433-- 8438.
  • 8Toyota M, Suzuki H, Sasaki Y, etal. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer [J]. Cancer Res, 2008,68 ( 11 ) : 4123 -- 4132.
  • 9Kumamoto K, Spillare EA, Fujita K, et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir- 34c expression ,and induce senescence[J]. Cancer Res, 2008,68 (9) - 3193-- 3203.
  • 10Ye M, Hu DN, Tu LL, et al. Involvement of PI3K/ Akt signaling pathway in hepatocyte growth factor- induced migration of uveal melanoma cells[J]. Invest Ophthalmol Vis Sci, 2008,49 (2) : 497-- 504.

共引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部